February 22 – 24, 2019, Miami, FL
The First Annual Miami General Medical Oncology Symposium
Please note that slides are for review only and not to be repurposed or published.
Keynote
Dr Porter
Chimeric Antigen Receptor (CAR) T-Cell Therapy and the General Medical Oncologist
Dr Kaufman
Targeting the Immune System in Myeloma: New CAR T Cells
Dr Neelapu
CAR T-Cell Therapy for B-Cell Lymphomas
Module 1: Colorectal and Gastric Cancer
Colorectal Cancer — Dr Fuchs
Gastric, Gastroesophageal Junction and Esophageal Cancer — Dr Enzinger
Module 2: Hepatocellular Carcinoma
Anti-VEGF-Directed Therapy — Dr El-Khoueiry
Immune Checkpoint Inhibitors — Dr Greten
Module 3: Melanoma
Adjuvant Therapy — Dr Lipson
Metastatic Disease — Dr Daud
Module 4: Chronic Lymphocytic Leukemia (CLL)
Newly Diagnosed CLL — Dr Davids
Management of Relapsed/Refractory CLL and Investigational Approaches — Dr Jain
Module 5: Hodgkin and Non-Hodgkin Lymphomas
Follicular Lymphoma — Dr Leonard
Mantle Cell Lymphoma and Hodgkin Lymphoma — Dr Moskowitz
Module 6: Ovarian Cancer (OC)
Current and Future Role of PARP Inhibitors in the Treatment of OC — Dr Coleman
Other Recently Approved and Promising Investigational Strategies — Dr Matulonis
Module 7: Pancreatic Cancer
Neoadjuvant and Adjuvant Therapy — Dr Ko
Metastatic Disease — Dr Philip
Module 8: ER-Positive, HER2-Negative Breast Cancer (BC)
Recent Clinical Trial Results Guiding the Use of Genomic Classifiers in the Management of Early BC; Ongoing Evaluation of CDK4/6 Inhibition in Earlier-Stage Disease — Dr Burstein
Sequence and Selection of Systemic Therapy for Patients with ER-Positive Metastatic BC; Novel Agents in Development — Dr Sledge
Module 9: HER2-Positive and Triple-Negative BC
Triple-Negative BC; PARP Inhibition in the Management of BC — Dr Winer
HER2-Positive Disease — Dr O’Shaughnessy
Module 10: Acute Myeloid Leukemia
Current Testing Algorithms; Treatment for Patients with a Genomic Alteration — Dr Stone
Recently Approved and Emerging Therapeutic Approaches — Dr Pollyea
Module 11: Prostate Cancer (PC)
Nonmetastatic Castration-Resistant PC (CRPC) and Metastatic Hormone-Sensitive PC — Dr Hussain
Key Issues in the Treatment of Metastatic CRPC — Dr Sartor
Module 12: Renal Cell and Bladder Cancer
Renal Cell Cancer — Dr Quinn
Urothelial Bladder Cancer — Dr Plimack
Module 13: Targeted Treatment of Lung Cancer
Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation — Dr Oxnard
Other Actionable Abnormalities in NSCLC — Dr Sequist
Module 14: Immune Checkpoint Inhibitors in Lung Cancer
Locally Advanced NSCLC; Metastatic Small Cell Lung Cancer — Dr Gubens
Metastatic NSCLC — Dr Neal
Live Poll Results
Saturday
Download
Sunday
Download
Download All